Shots:
EditForce to receive ~$147.3M up front and milestones upon the development stage and commercialization progress along with royalties
Under the terms of collaboration, MTPC to get an exclusive right to conduct the selection of drug candidate molecules, preclinical, clinical development, manufacturing, and commercialization globally
The companies focus on research, developing, and commercializing gene therapy products for the specific CNS disease by using EditForce’s PPR protein platform technology along with drug R&D and global business experience of MTPC
Ref: PRNewswire | Image: Mitsubishi Tanabe
